| There exists a very high risk of bias across the individual studies considering an improvement in the gastrointestinal quality of life for patients converting between mycophenolate mofetil and enteric-coated mycophenolate sodium for maintenance immunosuppression. |
| This study demonstrates that there is no good evidence supporting the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium for the improvement in patient-reported gastrointestinal outcomes. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.